These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

79 related articles for article (PubMed ID: 25831758)

  • 1. [Anti-vascular endothelial growth factor antibody].
    Kumagai H; Kusaba H; Baba E
    Nihon Rinsho; 2015 Feb; 73 Suppl 2():229-34. PubMed ID: 25831758
    [No Abstract]   [Full Text] [Related]  

  • 2. [anti-angiogenic drugs].
    Sato S
    Nihon Yakurigaku Zasshi; 2012 Apr; 139(4):184-5. PubMed ID: 22891390
    [No Abstract]   [Full Text] [Related]  

  • 3. [Are antiangiogenic antibodies universal for solid tumor?].
    Ray-Coquard I; Bachelot T; Saba C; Confavreux C; Brantus JF; Rustam F; Ghesquière H; Sebban C; Biron P; Guastalla JP; Blay JY
    Bull Cancer; 2007 Jul; 94 Spec No():S191-6. PubMed ID: 17846004
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting angiogenesis driven by vascular endothelial growth factors using antibody-based therapies.
    Grothey A; Ellis LM
    Cancer J; 2008; 14(3):170-7. PubMed ID: 18536556
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Anti-angiogenic therapy in breast cancer].
    Tanaka R; Tamura K
    Gan To Kagaku Ryoho; 2014 Feb; 41(2):153-6. PubMed ID: 24743193
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [The actual place of anti-angiogenesis in non-small cell lung cancer].
    Mennecier B
    Rev Mal Respir; 2007 Oct; 24(8 Pt 2):6S198-205. PubMed ID: 18235414
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The clinical toxicity profile of vascular endothelial growth factor (VEGF) and vascular endothelial growth factor receptor (VEGFR) targeting angiogenesis inhibitors; a review.
    Eskens FA; Verweij J
    Eur J Cancer; 2006 Dec; 42(18):3127-39. PubMed ID: 17098419
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antivascular endothelial growth factor-a treatment: new perspectives for high-risk plaque stabilization.
    Toutouzas K; Karabelas J; Vaina S; Stefanadis C
    J Am Coll Cardiol; 2007 Jul; 50(2):186. PubMed ID: 17616305
    [No Abstract]   [Full Text] [Related]  

  • 9. Use of anti-VEGF adjuvant therapy in cancer: challenges and rationale.
    Bagri A; Kouros-Mehr H; Leong KG; Plowman GD
    Trends Mol Med; 2010 Mar; 16(3):122-32. PubMed ID: 20189876
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Technology evaluation: bevacizumab, Genentech/Roche.
    Salgaller ML
    Curr Opin Mol Ther; 2003 Dec; 5(6):657-67. PubMed ID: 14755893
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical development of vascular disrupting agents: what lessons can we learn from ASA404?
    Lorusso PM; Boerner SA; Hunsberger S
    J Clin Oncol; 2011 Aug; 29(22):2952-5. PubMed ID: 21709201
    [No Abstract]   [Full Text] [Related]  

  • 12. Angiogenesis inhibition in solid tumors.
    Rosen LS
    Cancer J; 2001; 7 Suppl 3():S120-8. PubMed ID: 11779082
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Current overview of angiogenesis inhibitors.
    Ellis LM
    Clin Adv Hematol Oncol; 2004 Aug; 2(8):494-6, 520. PubMed ID: 16163228
    [No Abstract]   [Full Text] [Related]  

  • 14. Therapeutic anti-VEGF antibodies.
    Lien S; Lowman HB
    Handb Exp Pharmacol; 2008; (181):131-50. PubMed ID: 18071944
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Tyrosine kinase inhibitors in tumor therapy--part 2. Current position and perspectives].
    Grimm CF; Blum HE; Geissler M
    Dtsch Med Wochenschr; 2005 Jun; 130(23):1438-42. PubMed ID: 15929020
    [No Abstract]   [Full Text] [Related]  

  • 16. Mechanisms of resistance to vascular endothelial growth factor blockade.
    Abdullah SE; Perez-Soler R
    Cancer; 2012 Jul; 118(14):3455-67. PubMed ID: 22086782
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anti-vascular endothelial growth factor antibody bevacizumab reduced the risk of anemia associated with chemotherapy-A meta-analysis.
    Sher A; Wu S
    Acta Oncol; 2011 Oct; 50(7):997-1005. PubMed ID: 21554028
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Current concerns and challenges regarding tailored anti-angiogenic therapy in cancer.
    Roukos DH; Tzakos A; Zografos G
    Expert Rev Anticancer Ther; 2009 Oct; 9(10):1413-6. PubMed ID: 19828000
    [No Abstract]   [Full Text] [Related]  

  • 19. Anti-vascular endothelial growth factor therapy in the era of personalized medicine.
    Féliz LR; Tsimberidou AM
    Cancer Chemother Pharmacol; 2013 Jul; 72(1):1-12. PubMed ID: 23463481
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pathways mediating resistance to vascular endothelial growth factor-targeted therapy.
    Ellis LM; Hicklin DJ
    Clin Cancer Res; 2008 Oct; 14(20):6371-5. PubMed ID: 18927275
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.